Syed N - Search Results

1

Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM.

Przystal JM, Hajji N, Khozoie C, Renziehausen A, Zeng Q, Abaitua F, Hajitou A, Suwan K, Want E, Bomalaski J, Szlosarek P, O'Neill K, Crook T, Syed N. Przystal JM, et al. Among authors: syed n. Cell Death Dis. 2018 Dec 13;9(12):1192. doi: 10.1038/s41419-018-1195-4. Cell Death Dis. 2018. PMID: 30546006 Free PMC article.

2

p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.

Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T. Bergamaschi D, et al. Among authors: syed n. Cancer Cell. 2003 Apr;3(4):387-402. doi: 10.1016/s1535-6108(03)00079-5. Cancer Cell. 2003. PMID: 12726864 Free article.

3

Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo.

Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X, Crook T. Sullivan A, et al. Among authors: syed n. Oncogene. 2004 Apr 22;23(19):3328-37. doi: 10.1038/sj.onc.1207428. Oncogene. 2004. PMID: 15077186

4

DRAM, a p53-induced modulator of autophagy, is critical for apoptosis.

Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR, Gasco M, Garrone O, Crook T, Ryan KM. Crighton D, et al. Among authors: syed n. Cell. 2006 Jul 14;126(1):121-34. doi: 10.1016/j.cell.2006.05.034. Cell. 2006. PMID: 16839881 Free article.

5

Epigenetic inactivation implies a tumor suppressor function in hematologic malignancies for Polo-like kinase 2 but not Polo-like kinase 3.

Smith P, Syed N, Crook T. Smith P, et al. Among authors: syed n. Cell Cycle. 2006 Jun;5(12):1262-4. doi: 10.4161/cc.5.12.2813. Cell Cycle. 2006. PMID: 16868416

6

Epigenetics: an emerging technology in the diagnosis and treatment of cancer.

Stebbing J, Bower M, Syed N, Smith P, Yu V, Crook T. Stebbing J, et al. Among authors: syed n. Pharmacogenomics. 2006 Jul;7(5):747-57. doi: 10.2217/14622416.7.5.747. Pharmacogenomics. 2006. PMID: 16886899 Review.

7

Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.

Iorns E, Turner NC, Elliott R, Syed N, Garrone O, Gasco M, Tutt AN, Crook T, Lord CJ, Ashworth A. Iorns E, et al. Among authors: syed n. Cancer Cell. 2008 Feb;13(2):91-104. doi: 10.1016/j.ccr.2008.01.001. Cancer Cell. 2008. PMID: 18242510 Free article.

8

Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.

Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, Szlosarek P, McNeish I, Blagden SP, Schmid P, Lovell DP, Hatzimichael E, Crook T. Syed N, et al. Cancer Res. 2011 May 1;71(9):3317-27. doi: 10.1158/0008-5472.CAN-10-2048. Epub 2011 Mar 14. Cancer Res. 2011. PMID: 21402713 Free article.

9

Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.

Coley HM, Hatzimichael E, Blagden S, McNeish I, Thompson A, Crook T, Syed N. Coley HM, et al. Among authors: syed n. Oncotarget. 2012 Jan;3(1):78-83. doi: 10.18632/oncotarget.332. Oncotarget. 2012. PMID: 22289679 Free PMC article. Review.

10

Proteasome inhibition in cancer is associated with enhanced tumor targeting by the adeno-associated virus/phage.

Przystal JM, Umukoro E, Stoneham CA, Yata T, O'Neill K, Syed N, Hajitou A. Przystal JM, et al. Among authors: syed n. Mol Oncol. 2013 Feb;7(1):55-66. doi: 10.1016/j.molonc.2012.08.001. Epub 2012 Aug 21. Mol Oncol. 2013. PMID: 22951279 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

722 results

Search Page

Filters